Windlas Biotech: CDMO Compounder Hiding in Plain Sight
Everyone wants to own the next Cipla or Sun Pharma. Nobody wants to own the company that actually makes the pills those brands sell. That’s exactly why Windlas Biotech is interesting. At ₹867 (April 17, 2026), the stock sits ~24% below its 52-week high of ₹1,140, trading at ~27x trailing earnings, a ~3.4x price-to-book, and […]